Wall Street brokerages expect DexCom, Inc. (NASDAQ:DXCM) to announce sales of $246.68 million for the current quarter, according to Zacks. Eight analysts have provided estimates for DexCom’s earnings, with the highest sales estimate coming in at $286.70 million and the lowest estimate coming in at $232.80 million. DexCom reported sales of $184.40 million during the same quarter last year, which would suggest a positive year over year growth rate of 33.8%. The business is scheduled to report its next earnings results on Wednesday, May 1st.
On average, analysts expect that DexCom will report full year sales of $1.21 billion for the current fiscal year, with estimates ranging from $1.18 billion to $1.25 billion. For the next financial year, analysts expect that the firm will report sales of $1.43 billion, with estimates ranging from $1.32 billion to $1.51 billion. Zacks Investment Research’s sales calculations are an average based on a survey of research firms that cover DexCom.
Get DexCom alerts:DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 21st. The medical device company reported $0.54 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.16 by $0.38. The firm had revenue of $338.00 million for the quarter, compared to analyst estimates of $331.60 million. DexCom had a negative net margin of 12.32% and a positive return on equity of 5.42%. The business’s revenue for the quarter was up 52.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.10 EPS.
DXCM has been the topic of several analyst reports. BidaskClub raised shares of DexCom from a “hold” rating to a “buy” rating in a research report on Saturday, November 10th. Oppenheimer reaffirmed a “buy” rating on shares of DexCom in a research report on Wednesday, November 21st. UBS Group initiated coverage on shares of DexCom in a research report on Tuesday, November 27th. They set a “neutral” rating and a $135.00 price target on the stock. Morgan Stanley reduced their price target on shares of DexCom from $150.00 to $135.00 and set an “equal weight” rating on the stock in a research report on Wednesday, January 2nd. Finally, Piper Jaffray Companies lifted their price target on shares of DexCom to $165.00 and gave the company an “overweight” rating in a research report on Wednesday, January 9th. Seven analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $149.53.
Shares of DXCM stock traded up $0.17 during trading on Wednesday, hitting $143.24. 740,961 shares of the stock traded hands, compared to its average volume of 1,281,315. The firm has a market cap of $12.73 billion, a PE ratio of 477.47 and a beta of 0.84. The company has a debt-to-equity ratio of 0.60, a quick ratio of 4.43 and a current ratio of 4.71. DexCom has a 52-week low of $58.78 and a 52-week high of $156.16.
In other DexCom news, EVP Steven Robert Pacelli sold 1,667 shares of the business’s stock in a transaction on Friday, February 22nd. The shares were sold at an average price of $144.67, for a total value of $241,164.89. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kevin R. Sayer sold 11,162 shares of the business’s stock in a transaction on Monday, December 10th. The stock was sold at an average price of $121.67, for a total transaction of $1,358,080.54. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,388 shares of company stock valued at $6,867,204. Insiders own 1.80% of the company’s stock.
Several hedge funds have recently modified their holdings of DXCM. Laurel Wealth Advisors LLC acquired a new position in shares of DexCom during the fourth quarter worth $26,000. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of DexCom during the fourth quarter worth $33,000. First Hawaiian Bank grew its stake in shares of DexCom by 75.6% during the fourth quarter. First Hawaiian Bank now owns 395 shares of the medical device company’s stock worth $47,000 after purchasing an additional 170 shares in the last quarter. Bremer Trust National Association acquired a new position in shares of DexCom during the fourth quarter worth $49,000. Finally, LS Investment Advisors LLC acquired a new position in shares of DexCom during the fourth quarter worth $67,000.
About DexCom
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Article: What is the 52-week high/low?
Get a free copy of the Zacks research report on DexCom (DXCM)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment